207 related articles for article (PubMed ID: 33204588)
1. Discovery of Benzyl Tetraphosphonate Derivative as Inhibitor of Human Factor Xia.
Kar S; Mottamal M; Al-Horani RA
ChemistryOpen; 2020 Nov; 9(11):1161-1172. PubMed ID: 33204588
[TBL] [Abstract][Full Text] [Related]
2. Sulfonated non-saccharide molecules and human factor XIa: Enzyme inhibition and computational studies.
Al-Horani RA; Parsaeian E; Mohammad M; Mottamal M
Chem Biol Drug Des; 2022 Jul; 100(1):64-79. PubMed ID: 35377529
[TBL] [Abstract][Full Text] [Related]
3. Allosteric inhibition of human factor XIa: discovery of monosulfated benzofurans as a class of promising inhibitors.
Argade MD; Mehta AY; Sarkar A; Desai UR
J Med Chem; 2014 Apr; 57(8):3559-69. PubMed ID: 24666186
[TBL] [Abstract][Full Text] [Related]
4. Lignosulfonic Acid Sodium Is a Noncompetitive Inhibitor of Human Factor XIa.
Kar S; Bankston P; Afosah DK; Al-Horani RA
Pharmaceuticals (Basel); 2021 Aug; 14(9):. PubMed ID: 34577586
[TBL] [Abstract][Full Text] [Related]
5. Sulfated pentagalloylglucoside is a potent, allosteric, and selective inhibitor of factor XIa.
Al-Horani RA; Ponnusamy P; Mehta AY; Gailani D; Desai UR
J Med Chem; 2013 Feb; 56(3):867-78. PubMed ID: 23316863
[TBL] [Abstract][Full Text] [Related]
6. A synthetic heparin mimetic that allosterically inhibits factor XIa and reduces thrombosis in vivo without enhanced risk of bleeding.
Al-Horani RA; Abdelfadiel EI; Afosah DK; Morla S; Sistla JC; Mohammed B; Martin EJ; Sakagami M; Brophy DF; Desai UR
J Thromb Haemost; 2019 Dec; 17(12):2110-2122. PubMed ID: 31397071
[TBL] [Abstract][Full Text] [Related]
7. Allosteric inhibition of factor XIa. Sulfated non-saccharide glycosaminoglycan mimetics as promising anticoagulants.
Al-Horani RA; Gailani D; Desai UR
Thromb Res; 2015 Aug; 136(2):379-87. PubMed ID: 25935648
[TBL] [Abstract][Full Text] [Related]
8. Designing allosteric inhibitors of factor XIa. Lessons from the interactions of sulfated pentagalloylglucopyranosides.
Al-Horani RA; Desai UR
J Med Chem; 2014 Jun; 57(11):4805-18. PubMed ID: 24844380
[TBL] [Abstract][Full Text] [Related]
9. Investigation of the anticoagulant activity of cyclic sulfated glycosaminoglycan mimetics.
Chiles R; Afosah DK; Al-Horani RA
Carbohydr Res; 2023 Jul; 529():108831. PubMed ID: 37209666
[TBL] [Abstract][Full Text] [Related]
10. Fragment-Based Lead Generation of 5-Phenyl-1
Wei Q; Zheng Z; Zhang S; Zheng X; Meng F; Yuan J; Xu Y; Huang C
Molecules; 2018 Aug; 23(8):. PubMed ID: 30103465
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212).
Pinto DJP; Orwat MJ; Smith LM; Quan ML; Lam PYS; Rossi KA; Apedo A; Bozarth JM; Wu Y; Zheng JJ; Xin B; Toussaint N; Stetsko P; Gudmundsson O; Maxwell B; Crain EJ; Wong PC; Lou Z; Harper TW; Chacko SA; Myers JE; Sheriff S; Zhang H; Hou X; Mathur A; Seiffert DA; Wexler RR; Luettgen JM; Ewing WR
J Med Chem; 2017 Dec; 60(23):9703-9723. PubMed ID: 29077405
[TBL] [Abstract][Full Text] [Related]
12. Characterization of a heparin-binding site on the catalytic domain of factor XIa: mechanism of heparin acceleration of factor XIa inhibition by the serpins antithrombin and C1-inhibitor.
Yang L; Sun MF; Gailani D; Rezaie AR
Biochemistry; 2009 Feb; 48(7):1517-24. PubMed ID: 19178150
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants.
Lin J; Deng H; Jin L; Pandey P; Quinn J; Cantin S; Rynkiewicz MJ; Gorga JC; Bibbins F; Celatka CA; Nagafuji P; Bannister TD; Meyers HV; Babine RE; Hayward NJ; Weaver D; Benjamin H; Stassen F; Abdel-Meguid SS; Strickler JE
J Med Chem; 2006 Dec; 49(26):7781-91. PubMed ID: 17181160
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Chromen-7-yl Furan-2-Carboxylate as a Potent and Selective Factor XIa Inhibitor.
Obaidullah AJ; Al-Horani RA
Cardiovasc Hematol Agents Med Chem; 2017 Nov; 15(1):40-48. PubMed ID: 28552062
[TBL] [Abstract][Full Text] [Related]
15. Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin.
Wong PC; Jiang X
Thromb Haemost; 2010 Aug; 104(2):302-10. PubMed ID: 20589316
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in the discovery and development of factor XI/XIa inhibitors.
Al-Horani RA; Afosah DK
Med Res Rev; 2018 Sep; 38(6):1974-2023. PubMed ID: 29727017
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of novel proline based factor XIa selective inhibitors as leads for potential new anticoagulants.
Hussain Z; Cooke AJ; Neelamkavil S; Brown L; Carswell E; Geissler WM; Guo Z; Hawes B; Kelly TM; Kiyoi Y; Lai K; Lesburg C; Pow E; Zang Y; Wood HB; Edmondson SD; Liu W
Bioorg Med Chem Lett; 2020 Aug; 30(16):127072. PubMed ID: 32340773
[TBL] [Abstract][Full Text] [Related]
18. Generation and characterization of aptamers targeting factor XIa.
Woodruff RS; Ivanov I; Verhamme IM; Sun MF; Gailani D; Sullenger BA
Thromb Res; 2017 Aug; 156():134-141. PubMed ID: 28644959
[TBL] [Abstract][Full Text] [Related]
19. Allosteric Inhibition as a New Mode of Action for BAY 1213790, a Neutralizing Antibody Targeting the Activated Form of Coagulation Factor XI.
Schaefer M; Buchmueller A; Dittmer F; Straßburger J; Wilmen A
J Mol Biol; 2019 Dec; 431(24):4817-4833. PubMed ID: 31655039
[TBL] [Abstract][Full Text] [Related]
20. Macromolecular substrate-binding exosites on both the heavy and light chains of factor XIa mediate the formation of the Michaelis complex required for factor IX-activation.
Sinha D; Marcinkiewicz M; Navaneetham D; Walsh PN
Biochemistry; 2007 Aug; 46(34):9830-9. PubMed ID: 17676929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
